8-K - Orchestra BioMed Holdings, Inc. | StockGist

Current Report Details

Event Type

Material Agreement+4 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

hereto and is incorporated herein by reference. The issuance of the Warrant, the Warrant Shares and the Private Placement Shares is exempt from the requirements

Material Agreement

Source Document

2.03

. Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information required by this item with re

Financing

7.01

of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, regardless

Regulation Fd

8.01

. Other Information. Certain Unaudited Preliminary June 30, 2025 Financial Results Although the Company’s financial results for the quarter ended June 30, 2025

Other Event

$33.9M

9.01

. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 4.1 Form of Warrant to be Issued to Ligand Pharmaceuticals Incorporated 4.2 Form o

Exhibits Only

Source Document

Exhibits (11)

10.1

EXHIBIT 10.1

10.2

EXHIBIT 10.2

10.3

EXHIBIT 10.3

10.4

EXHIBIT 10.4

10.5

EXHIBIT 10.5

10.6

EXHIBIT 10.6

10.7

EXHIBIT 10.7

4.1

EXHIBIT 4.1

4.2

EXHIBIT 4.2

8-K

FORM 8-K

99.1

EXHIBIT 99.1